Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
24 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND SGN 35 [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Condition: Lymphoma
Intervention: Drug: Brentuximab Vedotin
2 Recruiting Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Condition: Lymphoma
Intervention: Drug: Brentuximab vedotin & Rituximab
3 Available A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: brentuximab vedotin
4 Recruiting A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma
Conditions: HIV Infection;   HIV-associated Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: Doxorubicin Hydrochloride;   Drug: Vinblastine;   Drug: Dacarbazine
5 Recruiting A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: nivolumab
6 Recruiting Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
Condition: Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: Cyclophosphamide;   Drug: Adriamycin;   Drug: Oncovin;   Drug: Bleomycin;   Drug: Etoposide;   Drug: Procarbazine;   Drug: Prednisone;   Drug: G-CSF;   Radiation: 30 Grays
7 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
8 Recruiting A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
Condition: Hodgkin Disease
Interventions: Drug: brentuximab vedotin;   Drug: bendamustine;   Drug: dacarbazine;   Drug: nivolumab
9 Recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
Conditions: AIDS-Related Hodgkin Lymphoma;   CD30-Positive Neoplastic Cells Present;   Classical Hodgkin Lymphoma;   HIV Infection;   Stage II Hodgkin Lymphoma;   Stage IIA Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage III Hodgkin Lymphoma;   Stage IIIA Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IV Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vinblastine
10 Recruiting Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab vedotin (SGN-35);   Drug: Doxorubicin HCL;   Drug: Vinblastine Sulfate;   Drug: Dacarbazine;   Radiation: Involved-Site Radiation Therapy (ISRT);   Procedure: Interim PET;   Radiation: consolidation volume RT (CVRT)
11 Recruiting Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Conditions: Hodgkin Lymphoma;   Refractory;   Relapse
Interventions: Drug: DHAP;   Drug: Brentuximab Vedotin;   Other: Autologous Peripheral Blood Stem Cell Transplantation
12 Not yet recruiting Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   Systemic Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Ceritinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
13 Recruiting Brentuximab Vedotin, Cyclosporine, and Verapamil in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Verapamil
14 Recruiting Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Ibrutinib
15 Recruiting Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
16 Recruiting A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone
17 Recruiting Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
18 Recruiting Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
19 Recruiting A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen
Condition: Lymphatic Diseases
Interventions: Drug: Brentuximab Vedotin;   Drug: Bendamustine
20 Recruiting Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
Conditions: Classical Hodgkin Lymphoma;   Stage IB Hodgkin Lymphoma;   Stage II Hodgkin Lymphoma;   Stage IIA Hodgkin Lymphoma;   Stage IIB Hodgkin Lymphoma;   Stage III Hodgkin Lymphoma;   Stage IIIA Hodgkin Lymphoma;   Stage IIIB Hodgkin Lymphoma;   Stage IV Hodgkin Lymphoma;   Stage IVA Hodgkin Lymphoma;   Stage IVB Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.